Numab Therapeutics AG Secures $54.6 Million in Series C Funding to Drive Innovations in Solid Tumor Cell Therapy

Numab Therapeutics AG is excited to announce a significant funding milestone, having secured $54.6 million in its latest investment round. Founded in 2018 by pioneering minds Alexander Kamb, Michael Gallo, and Paul Kang, Numab is at the forefront of innovative medicine, dedicated to redefining the landscape of cancer treatment. With a strong focus on advancing cell therapy for solid tumors, the company is committed to harnessing the power of engineered T cells. These specialized cells are designed to recognize and eliminate tumor cells that have lost specific genetic material, offering a targeted approach that minimizes impact on healthy tissue. This recent funding brings Numab's total capital raised since inception to an impressive $136 million, with support from a prestigious roster of investors, including The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments, and Hartford HealthCare Endowment. The new capital will be instrumental in advancing Numab's cutting-edge therapeutic platforms through the next stages of development and clinical trials. The company is poised to not only push the boundaries of oncology treatment but also to transform the lives of patients battling cancer. With this infusion of resources, Numab is steadily progressing toward achieving its vision of revolutionizing cancer care and providing hope through precise and effective treatment options.